The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features
- PMID: 19924504
- DOI: 10.1007/s10072-009-0182-z
The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features
Abstract
The Fattori di Rischio Ambientali e Genetici Associati alla Malattia di Parkinson (FRAGAMP) study is a multicenter case-control study carried out to evaluate the possible role of environmental and genetic factors in Parkinson's disease (PD). Cases and controls were enrolled from five Movement Disorder centers in Central-Southern Italy. PD was diagnosed according to Gelb's criteria while the control groups consisted of the spouses of the enrolled patients or of healthy controls matched by age and area of residence. Cases and controls underwent a standardised questionnaire and a blood sample was taken for molecular analyses. At the end of the study 585 cases and 481 control subjects (287 spouse-controls and 194 generic-controls) were enrolled. Patients had a Hoehn-Yahr score of 2.3 +/- 0.8; 85% of them took levodopa and 47% had motor complications. The FRAGAMP study represents one of the largest case-control studies carried out in Europe to investigate the possible role of environmental and genetic factors in PD.
Similar articles
-
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.J Neurol. 2016 May;263(5):888-894. doi: 10.1007/s00415-016-8075-6. Epub 2016 Mar 10. J Neurol. 2016. PMID: 26964541
-
Head trauma and Parkinson's disease: results from an Italian case-control study.Neurol Sci. 2017 Oct;38(10):1835-1839. doi: 10.1007/s10072-017-3076-5. Epub 2017 Jul 26. Neurol Sci. 2017. PMID: 28748275
-
Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.J Parkinsons Dis. 2018;8(1):59-70. doi: 10.3233/JPD-171181. J Parkinsons Dis. 2018. PMID: 29480220
-
Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1795-807. doi: 10.1016/j.pnpbp.2011.05.014. Epub 2011 May 30. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21645577 Review.
-
Levodopa strengths and weaknesses.Neurology. 2002 Feb 26;58(4 Suppl 1):S19-32. doi: 10.1212/wnl.58.suppl_1.s19. Neurology. 2002. PMID: 11909982 Review.
Cited by
-
Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.J Neurol. 2016 May;263(5):888-894. doi: 10.1007/s00415-016-8075-6. Epub 2016 Mar 10. J Neurol. 2016. PMID: 26964541
-
Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease.Sci Rep. 2021 Oct 1;11(1):19582. doi: 10.1038/s41598-021-99393-8. Sci Rep. 2021. PMID: 34599261 Free PMC article.
-
Head trauma and Parkinson's disease: results from an Italian case-control study.Neurol Sci. 2017 Oct;38(10):1835-1839. doi: 10.1007/s10072-017-3076-5. Epub 2017 Jul 26. Neurol Sci. 2017. PMID: 28748275
-
Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis.PLoS One. 2016 Apr 7;11(4):e0151841. doi: 10.1371/journal.pone.0151841. eCollection 2016. PLoS One. 2016. PMID: 27055126 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical